Literature DB >> 24828760

Response to "safety profile of intravenous patient-controlled analgesia for breathrough pain in cancer patients: a case series study".

Andrew Davies1.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 24828760     DOI： 10.1007/s00520-014-2283-3

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN： 0941-4355            Impact factor:   3.603


× No keyword cloud information.
  4 in total

1.  The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland.

Authors:  Andrew N Davies; Andrew Dickman; Colette Reid; Anna-Marie Stevens; Giovambattista Zeppetella
Journal:  Eur J Pain       Date:  2008-08-15       Impact factor: 3.931

Review 2.  Assessment and classification of cancer breakthrough pain: a systematic literature review.

Authors:  Dagny Faksvåg Haugen; Marianne Jensen Hjermstad; Neil Hagen; Augusto Caraceni; Stein Kaasa
Journal:  Pain       Date:  2010-03-16       Impact factor: 6.961

3.  Safety profile of intravenous patient-controlled analgesia for breakthrough pain in cancer patients: a case series study.

Authors:  Angela Maria Sousa; José de Santana Neto; Gabriel M N Guimaraes; Giovana M Cascudo; José Osvaldo B Neto; Hazem A Ashmawi
Journal:  Support Care Cancer       Date:  2013-11-21       Impact factor: 3.603

4.  Breakthrough cancer pain: an observational study of 1000 European oncology patients.

Authors:  Andrew Davies; Alison Buchanan; Giovambattista Zeppetella; Josep Porta-Sales; Rudolf Likar; Wolfgang Weismayr; Ondrej Slama; Tarja Korhonen; Marilene Filbet; Philippe Poulain; Kyriaki Mystakidou; Alexandros Ardavanis; Tony O'Brien; Pauline Wilkinson; Augusto Caraceni; Furio Zucco; Wouter Zuurmond; Steen Andersen; Anette Damkier; Tove Vejlgaard; Friedemann Nauck; Lukas Radbruch; Karl-Fredrik Sjolund; Mariann Stenberg
Journal:  J Pain Symptom Manage       Date:  2013-03-22       Impact factor: 3.612
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.